Triptorelin, already listed for prostate cancer, should have unrestricted use, the Pharmaceutical Benefits Advisory Committee says
Get our breaking news email, free app or daily news podcast
The federal government should fund treatment for thousands of women with breast cancer or endometriosis, and children with gender dysphoria, according to the Pharmaceutical Benefits Scheme’s advisory committee.
The committee met urgently in July in response to AstraZeneca’s announcement it would remove Zoladex from the market, risking leaving more than 7,500 women with breast cancer without an alternative treatment.
Continue reading...This article was originally published by The Guardian and written by Andrew Messenger.
Read original article on The Guardian